The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Osteoporosis International

• Publication date

  2010-03-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1007/s00198-009-0989-8PMID 19565175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Effectiveness of Alendronate (Fosamax®) for the Treatment of Osteoporosis and Prevention of Fractures

  2012cited by this paper
• 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

  2010cited by this paper
• Fracture risk remains reduced one year after discontinuation of risedronate

  2008cited by this paper
• Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK

  2008cited by this paper
• The cost-effectiveness of alendronate in the management of osteoporosis.

  2008cited by this paper
• FRAX™ and the assessment of fracture probability in men and women from the UK

  2008influential reference
• Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™)

  2008cited by this paper
• Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden

  2008cited by this paper
• Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA

  2008cited by this paper
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  2008cited by this paper
• Cost-effective osteoporosis treatment thresholds: the United States perspective

  2008cited by this paper
• Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial

  2007cited by this paper
• Effects of risedronate on fracture risk in postmenopausal women with osteopenia

  2007influential reference
• Diagnostik und Therapie der postmenopausalen Osteoporose und der Osteoporose des Mannes

  2007cited by this paper
• [Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006].

  2007cited by this paper
• The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women

  2007cited by this paper
• Non-compliance: the Achilles' heel of anti-fracture efficacy

  2007cited by this paper
• Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment.

  2007cited by this paper
• Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

  2006cited by this paper
• The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective

  2006cited by this paper
• Assessment of compliance with osteoporosis treatment and its consequences in a managed care population.

  2006cited by this paper
• Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model

  2006cited by this paper
• At what hip fracture risk is it cost-effective to treat?

  2006cited by this paper
• The hospitalisation costs and out-patient costs of fragility fractures

  2006cited by this paper
• An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting

  2006cited by this paper
• A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

  2005cited by this paper
• Intervention thresholds for osteoporosis in the UK.

  2005cited by this paper
• Guidelines for diagnosis and management of osteoporosis

  2005influential reference
• Costs and quality of life associated with osteoporosis-related fractures in Sweden

  2005cited by this paper
• Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden

  2004cited by this paper
• Problems with primary care data quality: osteoporosis as an exemplar.

  2004cited by this paper
• Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

  2004cited by this paper
• The risk and burden of vertebral fractures in Sweden

  2004cited by this paper
• Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

  2004influential reference
• Mortality after osteoporotic fractures

  2004cited by this paper
• Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.

  2003cited by this paper
• A New Approach to the Development of Assessment Guidelines for Osteoporosis

  2002cited by this paper
• The cost utility of bisphosphonate treatment in established osteoporosis.

  2002influential reference
• NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE)

  2002cited by this paper
• Treatment of established osteoporosis: a systematic review and cost-utility analysis.

  2002cited by this paper
• A new approach to the development of assessment guidelines for osteoporosis.

  2002cited by this paper
• The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds

  2001cited by this paper
• Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

  2001cited by this paper
• Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

  2000cited by this paper
• Health‐Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral Fractures

  2000cited by this paper
• A COMPUTER MODEL TO ANALYZE THE COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY

  1999cited by this paper
• Effect and Offset of Effect of Treatments for Hip Fracture on Health Outcomes

  1999cited by this paper
• Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

  1999cited by this paper
• Epidemiology of fractures in 15,000 adults: the influence of age and gender.

  1998cited by this paper
• Epidemiology of fractures in 15 000 adults: The influence of age and gender

  1998cited by this paper
• Lifetime Risk of Hip Fractures is Underestimated

  1998cited by this paper
• Variations in population health status: results from a United Kingdom national questionnaire survey

  1998cited by this paper
• Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.

  1997cited by this paper
• Cost-effectiveness of fracture prevention in established osteoporosis

  1995cited by this paper
• Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group.

  1992cited by this paper
• Which Fractures Are Associated with Low Appendicular Bone Mass in Elderly Women

  1991cited by this paper

• Cost-Effectiveness of Osteoporosis Treatment

  2021cites this paper
• Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal

  2020cites this paper
• Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly.

  2019cites this paper
• Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France

  2019cites this paper
• Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway

  2018cites this paper
• The Cost‐Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study

  2018cites this paper
• Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran

  2017cites this paper
• Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model

  2017cites this paper
• Worldwide Fracture Prediction.

  2017cites this paper
• A systematic review of intervention thresholds based on FRAX

  2016influential citation
• Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX

  2016cites this paper
• Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal

  2016cites this paper
• A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.

  2016cites this paper
• Relation between serum IL-17 level and risk of osteoporotic fracture in premenopausal rheumatoid arthritis patients: Clinical, radiological and laboratory studies

  2016cites this paper
• FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK

  2015cites this paper
• Health technology assessment in osteoporosis : new perspectives from adherence and preference studies

  2015influential citation
• El rol de la investigación en efectividad comparada (CER)

  2015cites this paper
• Tissue engineered bone using select growth factors: A comprehensive review of animal studies and clinical translation studies in man.

  2014cites this paper
• A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis

  2014cites this paper
• Bone forming agents for the management of osteoporosis.

  2014cites this paper
• The application of health technology assessment in osteoporosis.

  2014cites this paper
• A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions

  2014cites this paper
• Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis

  2013cites this paper
• A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures

  2013cites this paper
• Fracture Risk Assessment: The Development and Application of FRAX®

  2013cites this paper
• Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria

  2013cites this paper
• Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm

  2013cites this paper
• Cost-Effectiveness of Alendronate and Risedronate for Primary Prevention of Fractures in Postmenopausal Women

  2013influential citation
• What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture?

  2013cites this paper
• A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

  2012cites this paper
• Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland

  2012cites this paper
• Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review.

  2012cites this paper
• Using WHO-FRAX to Describe Fracture Risk: Experience in Primary Care

  2012cites this paper
• Recommendations on the management of fragility fracture risk in women younger than 70 years

  2012cites this paper
• Effectiveness of osteoporosis therapy among frail, older adults: should we carry out more trials?

  2012cites this paper
• Current and future treatment options in osteoporosis

  2011cites this paper
• Osteoporosis: burden, health care provision and opportunities in the EU

  2011cites this paper
• Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study

  2011cites this paper
• The characteristics of osteoporotic fractures in the region of Bialystok (BOS-2). The application of the WHO algorithm, FRAX®BMI and FRAX®BMD assessment tools to determine patients for intervention.

  2011cites this paper
• The true cost of pharmacological disease prevention

  2011cites this paper
• Early postmenopausal bone loss and what to do about it

  2011cites this paper
• Partial adherence: a new perspective on health economic assessment in osteoporosis

  2011cites this paper
• Missed opportunities for osteoporosis management in older patients: a literature review

  2010cites this paper
• An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women

  2010influential citation
• Strontium ranelate: a look back at its use for osteoporosis

  2010cites this paper
• Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis

  2010cites this paper
• Recent advances in managing osteoporosis

  2009cites this paper
• Fall risk: the clinical relevance of falls and how to integrate fall risk with fracture risk.

  2009cites this paper
• FRAX and its applications to clinical practice.

  2009cites this paper
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  2008cites this paper
• Clinical Interventions in Aging Dovepress Bisphosphonate Use and Hip Fracture Epidemiology: Ecologic Proof from the Contrary

  year unknowncites this paper